Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020;256(1):49-77.
doi: 10.1016/bs.pbr.2020.05.027. Epub 2020 Jul 16.

A broad perspective on the molecular regulation of retinal ganglion cell degeneration in glaucoma

Affiliations
Review

A broad perspective on the molecular regulation of retinal ganglion cell degeneration in glaucoma

Gülgün Tezel. Prog Brain Res. 2020.

Abstract

Glaucoma is a complex neurodegenerative disease involving RGC axons, somas, and synapses at dendrites and axon terminals. Recent research advancements in the field have revealed a bigger picture of glaucomatous neurodegeneration that encompasses multiple stressors, multiple injury sites, multiple cell types, and multiple signaling pathways for asynchronous degeneration of RGCs during a chronic disease period. Optic nerve head is commonly viewed as the critical site of injury in glaucoma, where early injurious insults initiate distal and proximal signaling for axonal and somatic degeneration. Despite compartmentalized processes for degeneration of RGC axons and somas, there are intricate interactions between the two compartments and mechanistic overlaps between the molecular pathways that mediate degeneration in axonal and somatic compartments. This review summarizes the recent progress in the molecular understanding of RGC degeneration in glaucoma and highlights various etiological paths with biomechanical, metabolic, oxidative, and inflammatory components. Through this growing body of knowledge, the glaucoma community moves closer toward causative treatment of this blinding disease.

Keywords: Glaucoma; Molecular signaling; Neurodegeneration; Neuroinflammation; Optic nerve axons; Retinal ganglion cells.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

FIG. 1
FIG. 1
Neurodegeneration in glaucoma involves RGC axons, somas, and synapses at dendrites and axon terminals. The etiological framework of glaucomatous neurodegeneration encompasses multiple stressors (including elevated IOP, aging, genetic, epigenetic, systemic factors), multiple injury sites (optic nerve head, retina, brain), multiple cell types (including glial cells, vascular cells), and multiple signaling pathways for asynchronous degeneration of RGCs during a chronic disease period. A stressor threshold determines the individual susceptibility of RGCs to injury. Optic nerve head is the critical site of injury, and early injury of axons at the optic nerve head can initiate distal and proximal signaling for axonal and somatic degeneration of RGCs. A distal axonopathy is processed by Wallerian degeneration and dying back; however, degeneration of the proximal axon segment appears to be secondary to the apoptosis of RGC soma (that is processed through intrinsic/mitochondrial and extrinsic/dead receptor-mediated pathways). Despite compartmentalized molecular programs for degeneration of RGC axons and somas, there are mechanistic overlaps between the degeneration of RGC axons and somas, which include biomechanical, metabolic, oxidative, and inflammatory components.

Similar articles

Cited by

References

    1. Albalawi F, Lu W, Beckel JM, Lim JC, McCaughey SA, Mitchell CH, 2017. The P2X7 receptor primes IL-1beta and the NLRP3 inflammasome in astrocytes exposed to mechanical strain. Front. Cell. Neurosci 11, 227. - PMC - PubMed
    1. Baltan S, Inman DM, Danilov CA, Morrison RS, Calkins DJ, Horner PJ, 2010. Metabolic vulnerability disposes retinal ganglion cell axons to dysfunction in a model of glaucomatous degeneration. J. Neurosci 30, 5644–5652. - PMC - PubMed
    1. Baris M, Tezel G, 2019. Immunomodulation as a neuroprotective strategy for glaucoma treatment. Curr. Ophthalmol. Rep 7, 160–169. - PMC - PubMed
    1. Barrientos SA, Martinez NW, Yoo S, et al., 2011. Axonal degeneration is mediated by the mitochondrial permeability transition pore. J. Neurosci 31, 966–978. - PMC - PubMed
    1. Beirowski B, Babetto E, Coleman MP, Martin KR, 2008. The WldS gene delays axonal but not somatic degeneration in a rat glaucoma model. Eur. J. Neurosci 28, 1166–1179. - PubMed

Publication types

LinkOut - more resources